Use of Impedance Cardiography to Decrease the Risk of Pre-eclampsia in Obese Patients
Public ClinicalTrials.gov record NCT03105661. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Use of Impedance Cardiography to Decrease the Risk of Preeclampsia in Obese Patients
Study identification
- NCT ID
- NCT03105661
- Recruitment status
- Not listed
- Study type
- Interventional
- Phase
- Early Phase 1
- Lead sponsor
- University of Tennessee Graduate School of Medicine
- Other
- Enrollment
- 400 participants
Conditions and interventions
Conditions
Interventions
- Labetalol Hydrochloride 200 mg Drug
- NIFEdipine 60 mg Drug
- Atenolol 25 mg Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 51 Years
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 3, 2017
- Primary completion
- Dec 30, 2019
- Completion
- Mar 3, 2020
- Last update posted
- Feb 21, 2019
2017 – 2020
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Tennessee Medical Center | Knoxville | Tennessee | 37920 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03105661, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 21, 2019 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03105661 live on ClinicalTrials.gov.